Stock Analysis of Panbela Therapeutics Inc (PBLA)

Loading ...

Birds Eye View of Panbela Therapeutics Inc

Birds's Eye

Technical Analysis of Panbela Therapeutics Inc

Stock Analysis of Panbela Therapeutics Inc (PBLA) - Birds Eye View

1W 2W 1M 3M 1Y 2Y 5Y

Overview

Code	PBLA
Close	0.441
Change	0.0318 / 7.78 %
Volume	83494.00
Vol Change	57470.00 / 220.83 %
Industry	Biotechnology
Sector	Healthcare

AIO Strength Index

Technical Strength	Mild Bearish
Growth Index	Poor Growth Stock
Value Index	Poor Value Stock
Profitability Index	Poor Profitability Stock
Stability Index	Poor Stability Stock

Fundamental View of Panbela Therapeutics Inc

PE (TTM)

-14.32

Very Poor

Price / Book

-642.19

Very Poor

Price / Sales

0

Very Poor

Piotroski F Score

4.0

Indecisive

Market Cap

2140.02 K

Enterprise Value

4756.02 K

All Financial Ratio's

ROA (TTM)

-197.71

Very Poor

ROE (TTM)

0

Poor

Net Margin (TTM)

0

Poor

Revenue

100.00 %

Net Profit

27.68 %

-25263.00 K

Debt to Equity

-1.10

Very Poor

Altman Z Score

-22.75

Very Poor

Quick Ratio

0

Poor

Cash Ratio

0.209

Poor

Financial Statement Analysis

Highs/Lows of Panbela Therapeutics Inc

Period	Old price	Stock Return	S&P 500 Returns	High	Low	High Date	Low Date
One Week	0.409	7.78 %	1.54 %	0.4848	0.4065	14-May-24	14-May-24
Two Week	0.43	2.51 %	3.42 %	0.4848	0.3801	14-May-24	02-May-24
One Month	0.59	25.29 %	5.60 %	0.59	0.35	16-Apr-24	26-Apr-24
Three Month	1.36	67.59 %	5.95 %	1.41	0.35	15-Feb-24	26-Apr-24
Six Months	12.0	96.33 %	17.48 %	38.0	0.35	19-Dec-23	26-Apr-24
One year	228.0	99.81 %	27.52 %	246.0	0.35	16-May-23	26-Apr-24
Two year	38452.8	100.00 %	29.70 %	12739.2	0.35	26-Sep-22	26-Apr-24
Five year	58920.0	100.00 %	85.46 %	1170.0	0.2101	31-Jan-23	31-May-23

Technical View of Panbela Therapeutics Inc

RSI

38.70

Neutral

MACD

-0.105

Strong Bullish

ADX

24.65

Bullish

Super Trend

0.635

Mild Bearish

Williams %R

-43.25

Neutral

CCI

-28.70

Neutral

Technical Analysis Deep Dive

EMA 5

0.420

Strong Bullish

EMA 15

0.446

Mild Bearish

EMA 50

1.35

Mild Bearish

EMA 100

13.45

Mild Bearish

SMA 100

4.53

Mild Bearish

SMA 200

13.63

Mild Bearish

SMA 5 / 20

0.410 / 0.462

Mild Bearish

SMA 15 / 50

0.433 / 0.638

Mild Bearish

SMA 50 / 200

0.638 / 13.63

Strong Bearish

MA Analysis Deep Dive

Charts of Panbela Therapeutics Inc

Returns of Panbela Therapeutics Inc with Peers

Period / Stock	PBLA	BBLN	APDN	NAOV
1 Week	7.78%	-84.56%	-27.25%	4.95%
1 Mth	-25.29%	-86.18%	-62.31%	0.893%
3 Mth	-67.59%	-98.23%	-80.39%	-35.87%
6mth	-96.33%	-98.89%	-84.90%	-44.36%
1 Year	-99.81%	-99.67%	-89.09%	-79.96%
2 Year	-100.00%	-99.97%	-91.04%	-94.35%
5 Years	-100.00%	-	-99.44%	-98.83%
charts	-

View All Together in Chart Inline Tile

Compare Fundamentals of Panbela Therapeutics Inc with Peers

Ratio / Stock	PBLA	BBLN	APDN	NAOV
PE	-14.32	-0.0033	-0.143	-92.07
P/B	-642.19	-0.0099	0.345	92.46
ROA	-197.71	-113.00	-92.32	-56.33
ROE	0	0	-240.51	-100.42
Debt To Equity	-1.10	-1.11	0.102	0.0013
Revenue	0 100.00 %	1109.67 M 243.63 %	13367.44 K 26.43 %	1004.00 K 33.51 %
Net Income	-25263.00 K 27.68 %	-221449.00 K 39.90 %	-9947.06 K 18.73 %	-4957.00 K 9.01 %

Technicals of Panbela Therapeutics Inc with Peers

Technical / Stock	PBLA	BBLN	APDN	NAOV	-
ADX	24.65	42.16	33.09	19.37
CMF	-0.132	0.111	-0.321	-0.548
MFI	30.72	73.88	22.93	23.55
RSI	38.70	21.01	17.74	48.80
MACD Abv Signal	True	True	True	True
Price Above 50 MA	False	False	False	False	-
Price Above 200 MA	False	False	False	False	-

About : Panbela Therapeutics Inc

Address : 712 Vista Boulevard, Waconia, MN, United States, 55387
Tel : 952 479 1196
URL : https://www.panbela.com
Code : PBLA, ISIN : US69833W1071, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 03_Jan_2017
Employee Count : 7

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Note : All Data Generated at the End of Trading Hours (EOD Data)